JP#INBIORC2612A

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation and Prepares for Phase III Clinical Trial

Goldman Sachs Raises Earnings Forecast and Target Price for Innovent Biologics

CICC Maintains Overweight Industry Rating for Innovent Biologics, Anticipates Continued Revenue Growth

Innovent Biologics Q1 2026 Revenue Exceeds RMB 3.8 Billion with YoY Growth of Over 50%

BofA Securities Reports: CStone Pharmaceuticals Sees Strong February Drug Sales

Innosyn Biologics to Present Clinical Data on IBI363 and TYVYT at the 2026 ASCO Annual Meeting

Ede Ronald Hao Xi reduced holdings of Innovent Biologics to 1 million shares

Innovative Drug Margetide's Phase II Clinical Trial Results Published in Cell Journal

CICC Report Analyzes Innovent Biologics 2025 Performance and Provides Rating Recommendations

UBS Cuts CSB Biopharma EPS Forecast but Maintains Buy Rating

Citi Raises Rating and Target Price for Innovent Biologics

Goldman Sachs Report: Innovent Biologics Surpassed Revenue Expectations in H2 2022

INNOVENT BIO released FY2025 9 Months Earnings on March 26, 2026 (BJT) with actual revenue of HKD 6.446 B and EPS of HKD 0.5305

INNOVENT BIO released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 3.874 B, actual EPS HKD -0.0066

INNOVENT BIO released FY2025 Q4 earnings on March 26 After-Market (BJT), actual revenue HKD 3.941 B, actual EPS HKD -0.0067

INNOVENT BIO released FY2025 Annual Earnings on March 26 After-Market (BJT), Actual Revenue: HKD 14.25 B (Forecast: HKD 14.83 B), Actual EPS: HKD 0.5136 (Forecast: HKD 1.07)

Innovent Biologics Announces Profitable Year, Reversing Previous Losses

Innovent Biologics Clarifies Strategic Cooperation Agreement Not an Acquisition

JPMorgan Increases Stake in Innovent Biologics by 497,823 Shares

FAMEGLOW

ZHONGSHENJIANYE

TJCD

ZXZN QI-HOUSE

CENTRAL DEV H

HINSANG GROUP

NEW GONOW RV

JOLIMARK

MEGAIN

HAICHANG HLDG

01801

159316

159570

588130

588250

520690

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

prnewswire

INNOVENT BIO

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Tianhong CNI BIOMEDICINE ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

02509

603259

WXXWY

06990

588860

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

AASTOCKS News

QYUNS-B

WuXi AppTec

WuXi Biologics

WUXI APPTEC

SKB BIO

WUXI BIO

TEDA BIOMEDICAL

WUXI XDC

ICBCCS SSE STAR Biology and Medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

CICC analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$118.30.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$118.15.

Tip Ranks

CICC

CICC Sticks to Their Buy Rating for Innovent Biologics (IVBXF)

G Sachs has raised the target price for INNOVENT BIOto HKD105.94 following a strong 1Q26 performance, where product revenue exceeded RMB3.8 billion, up over 50% YoY. This surpassed the broker's forecast of RMB3.5 billion, driven by product portfolio expansion. G Sachs also increased EPS forecasts for 2026 to 2028 and maintained a Buy rating. Key data releases in June at the ADA and ASCO conferences are anticipated to attract market attention.

Goldman Sachs

GS Hldg R

G Sachs Raises INNOVENT BIO  TP to HKD105.94; 1Q Product Sales Beat

INNOVENT BIOreported a product revenue exceeding RMB3.8 billion in 1Q26, marking a year-on-year increase of over 50%. This growth is attributed to the inclusion of five tyrosine kinase inhibitors in the National Reimbursement Drug List, leading to rapid volume expansion. Key products driving revenue include Sintilimab, Xinbile, and Xinbimin. The company is also advancing three promising molecules into Phase III clinical trials and continues to invest in early-stage innovations across various therapeutic areas.

INNOVENT BIO  1Q26 Product Revenue Exceeds RMB3.8 billion, Up Over 50% YoY

01888

02338

01171

02513

00857

09926

00100

06082

09868

KB LAMINATES(01888) rose 10.63%, with a trading turnover 1.8 Billion HKD, and a year-to-date rose 158.8%. WEICHAI POWER(02338) rose 6.76%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 87.6%. AKESO(09926) fell 12.66%, with a trading turnover 3.1 Billion HKD, and a year-to-date rose 15.4%. MINIMAX-W(00100) fell 7.49%, with a trading turnover 1.5 Billion HKD, and a year-to-date rose 420.3%.

- The Hang Seng Index fell by 0.95%, with a year-to-date increase of 1.1%, while the Hang Seng Tech Index decreased by 1.98%, down 11.8% for the year.  
- Jian Tao Jici Ban (01888) rose by 10.63% with a trading volume of 1.76 billion HKD, marking a 158.8% year-to-date increase.  
- Weichai Power (02338) increased by 6.76% with a trading volume of 1.06 billion HKD, showing a 87.6% year-to-date rise, whereas Kangfang Biotech (09926) declined by 12.66%.

Top Gainers&Losers

KB LAMINATES

WEICHAI POWER

YANKUANG ENERGY

KNOWLEDGE ATLAS

PETROCHINA

AKESO

MINIMAX-W

BIREN TECH

XPENG-W

Top 5 HK Stock Gainers/Losers (>100B) (4.23)

06181

01177

03317

06869

01772

SKB BIO(06990) rose 6.97%, with a trading turnover 458.1 Million HKD, and a year-to-date rose 32.3%. AKESO(09926) rose 6.89%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 30.4%. MINIMAX-W(00100) fell 10.88%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 413.6%. KNOWLEDGE ATLAS(02513) fell 8.54%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 646.1%.

LAOPU GOLD

SBP GROUP

XUNCE

YOFC

GANFENGLITHIUM

Top 5 HK Stock Gainers/Losers (>100B) (4.15)

00883

002594

JP Morgan released a report listing the latest preferred stocks of Chinese companies, all of which have been given a "buy" rating. The list includes CNOOC, target price HKD 33; BYD, target price HKD 120; Northern Huachuang, target price RMB 610; MINIMAX-W, target price HKD 1,100; Zhizhu, target price HKD 950; Bank of China, target price HKD 5.5; INNOVENT BIO, target price HKD 111

AASTOCKS

CNOOC

JP Morgan lists the latest preferred stocks of Chinese companies (Table)

JP#INBIORC2612A(59637.HK)